{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T21:09:16Z","timestamp":1775077756354,"version":"3.50.1"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Natriuretic peptides (NPs) are central to the diagnostic and therapeutic management of heart failure (HF), yet their short-term dynamics under sacubitril\/valsartan (S\/V) therapy and during acute volume changes remain incompletely characterized. We aimed to assess changes in circulating biomarkers and response to standardized acute intravascular volume expansion and diuretic treatment before and after S\/V initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We studied 229 ambulatory patients with HF with reduced ejection fraction receiving guideline-directed medical therapy who initiated S\/V. Patients were evaluated at three outpatient visits: before S\/V initiation and after 2 and 3 months of treatment. At each visit, participants underwent a standardized 9-hour protocol including volume infusion followed by diuretic administration. BNP, NT-proBNP, MR-proANP, and neprilysin activity were measured serially alongside clinical assessment and natriuresis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Across visits, initiation of S\/V was associated with lower concentrations of BNP (\u22128%, P = .009) and NT-proBNP (\u221235%, P &amp;lt; .001). During the acute protocol, both BNP and NT-proBNP increased significantly over time (timepoint effect P &amp;lt; .001), with parallel trajectories before and after S\/V initiation and no visit-by-time interaction (P = .17 for BNP; P = .95 for NT-proBNP). Despite marked natriuresis and improvement in clinical signs following diuretic administration, BNP and NT-proBNP continued to rise during the 9-hour observation period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In a controlled acute volume overload setting, BNP and NT-proBNP provide comparable information, but their short-term dynamics lag behind clinical decongestion. Routine serial NP measurements at very short time intervals are unlikely to add incremental clinical value in the early phase of acute HF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eschf\/xvag075","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T12:35:02Z","timestamp":1773491702000},"source":"Crossref","is-referenced-by-count":0,"title":["Cardiac biomarkers response under angiotensin receptor\u2013neprilysin inhibitor: a sub-analysis of the NATRIUM-HF study"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6356-2284","authenticated-orcid":false,"given":"Jolie","family":"Bruno","sequence":"first","affiliation":[{"name":"INSERM UMR-S 942, Cardiovascular Markers in Stress Condition (MASCOT) , 2 rue Ambroise Par\u00e9, Paris 75010 ,","place":["France"]},{"name":"Universit\u00e9 de Paris Cit\u00e9 , 45 Rue des Saints-P\u00e8res, Paris 75006 ,","place":["France"]},{"name":"Department of Anesthesiology, Critical Care and Burn Unit, University Hospitals Saint-Louis et Lariboisi\u00e8re, AP-HP , 1 Av. Claude Vellefaux, Paris 75010 ,","place":["France"]},{"name":"Department of Cardiology, Inselspital, Bern University Hospital, University of Bern , Freiburgstrasse 20, Bern 3010 ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aziz","family":"Daghmouri","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Critical Care, Groupment Hospitalier de Territoire Grand Paris Nord-Est, H\u00f4pital Andr\u00e9 Gr\u00e9goire , Montreuil ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malha","family":"Sadoune","sequence":"additional","affiliation":[{"name":"INSERM UMR-S 942, Cardiovascular Markers in Stress Condition (MASCOT) , 2 rue Ambroise Par\u00e9, Paris 75010 ,","place":["France"]},{"name":"Universit\u00e9 de Paris Cit\u00e9 , 45 Rue des Saints-P\u00e8res, Paris 75006 ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romane","family":"Lafontaine","sequence":"additional","affiliation":[{"name":"INSERM UMR-S 942, Cardiovascular Markers in Stress Condition (MASCOT) , 2 rue Ambroise Par\u00e9, Paris 75010 ,","place":["France"]},{"name":"Universit\u00e9 de Paris Cit\u00e9 , 45 Rue des Saints-P\u00e8res, Paris 75006 ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexis","family":"Nguyen","sequence":"additional","affiliation":[{"name":"INSERM UMR-S 942, Cardiovascular Markers in Stress Condition (MASCOT) , 2 rue Ambroise Par\u00e9, Paris 75010 ,","place":["France"]},{"name":"Universit\u00e9 de Paris Cit\u00e9 , 45 Rue des Saints-P\u00e8res, Paris 75006 ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Edwards","sequence":"additional","affiliation":[{"name":"Momentum Research, Inc. , Durham, NC ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth","family":"Davison","sequence":"additional","affiliation":[{"name":"Momentum Research, Inc. , Durham, NC ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gad","family":"Cotter","sequence":"additional","affiliation":[{"name":"Momentum Research, Inc. , Durham, NC ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Takagi","sequence":"additional","affiliation":[{"name":"Momentum Research, Inc. , Durham, NC ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4339-2238","authenticated-orcid":false,"given":"Christos","family":"Varounis","sequence":"additional","affiliation":[{"name":"Abbott Laboratories , Chicago, IL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyanka","family":"Morishetty","sequence":"additional","affiliation":[{"name":"Momentum Research, Inc. , Durham, NC ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feriel","family":"Azibani","sequence":"additional","affiliation":[{"name":"INSERM UMR-S 942, Cardiovascular Markers in Stress Condition (MASCOT) , 2 rue Ambroise Par\u00e9, Paris 75010 ,","place":["France"]},{"name":"Universit\u00e9 de Paris Cit\u00e9 , 45 Rue des Saints-P\u00e8res, Paris 75006 ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Masson","sequence":"additional","affiliation":[{"name":"Biochemistry Laboratory, University Hospitals Saint-Louis et Lariboisi\u00e8re, AP-HP , Paris ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camille","family":"Chenevier-Gobeaux","sequence":"additional","affiliation":[{"name":"Biochemistry Laboratory, Cochin Hospital, AP-HP , Paris ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8715-7753","authenticated-orcid":false,"given":"Alexandre","family":"Mebazaa","sequence":"additional","affiliation":[{"name":"INSERM UMR-S 942, Cardiovascular Markers in Stress Condition (MASCOT) , 2 rue Ambroise Par\u00e9, Paris 75010 ,","place":["France"]},{"name":"Universit\u00e9 de Paris Cit\u00e9 , 45 Rue des Saints-P\u00e8res, Paris 75006 ,","place":["France"]},{"name":"Department of Anesthesiology, Critical Care and Burn Unit, University Hospitals Saint-Louis et Lariboisi\u00e8re, AP-HP , 1 Av. Claude Vellefaux, Paris 75010 ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5879-6369","authenticated-orcid":false,"given":"Benjamin","family":"Deniau","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris Cit\u00e9 , 45 Rue des Saints-P\u00e8res, Paris 75006 ,","place":["France"]},{"name":"Department of Anesthesiology, Critical Care and Burn Unit, University Hospitals Saint-Louis et Lariboisi\u00e8re, AP-HP , 1 Av. Claude Vellefaux, Paris 75010 ,","place":["France"]},{"name":"INSERM PARCC UMR 970 , Paris ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"key":"2026040114443761600_xvag075-B1","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026040114443761600_xvag075-B2","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1002\/ejhf.2848","article-title":"Natriuretic peptides: role in the diagnosis and management of heart failure: a scientific statement from the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society","volume":"25","author":"Tsutsui","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026040114443761600_xvag075-B3","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1093\/cvr\/cvac187","article-title":"Mechanisms of current therapeutic strategies for heart failure: more questions than answers?","volume":"118","author":"Khan","year":"2023","journal-title":"Cardiovasc Res"},{"key":"2026040114443761600_xvag075-B4","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026040114443761600_xvag075-B5","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"2026040114443761600_xvag075-B6","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1161\/CIRCULATIONAHA.119.039920","article-title":"Prognostic implications of congestion on physical examination among contemporary patients with heart failure and reduced ejection fraction: PARADIGM-HF","volume":"140","author":"Selvaraj","year":"2019","journal-title":"Circulation"},{"key":"2026040114443761600_xvag075-B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacc.2023.04.019","article-title":"Angiotensin-neprilysin inhibition in patients with mildly reduced or preserved ejection fraction and worsening heart failure","volume":"82","author":"Mentz","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026040114443761600_xvag075-B8","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.3390\/jcm11113192","article-title":"Brain natriuretic peptide biomarkers in current clinical and therapeutic scenarios of heart failure","volume":"11","author":"Alcidi","year":"2022","journal-title":"J Clin Med"},{"key":"2026040114443761600_xvag075-B9","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s10741-021-10105-w","article-title":"Biomarkers for the diagnosis and management of heart failure","volume":"27","author":"Castiglione","year":"2022","journal-title":"Heart Fail Rev"},{"key":"2026040114443761600_xvag075-B10","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/nrcardio.2016.200","article-title":"Long-term neprilysin inhibition\u2014implications for ARNIs","volume":"14","author":"Campbell","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"2026040114443761600_xvag075-B11","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1161\/CIRCRESAHA.122.320882","article-title":"proANP metabolism provides new insights into sacubitril\/valsartan mode of action","volume":"130","author":"Michel","year":"2022","journal-title":"Circ Res"},{"key":"2026040114443761600_xvag075-B12","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1093\/clinchem\/hvac225","article-title":"Deconvolution of BNP and NT-proBNP immunoreactivities by mass spectrometry in heart failure and sacubitril\/valsartan treatment","volume":"69","author":"Nougu\u00e9","year":"2023","journal-title":"Clin Chem"},{"key":"2026040114443761600_xvag075-B13","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1042\/bj2910083","article-title":"Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11","volume":"291","author":"Kenny","year":"1993","journal-title":"Biochem J"},{"key":"2026040114443761600_xvag075-B14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1006\/bmme.1997.2584","article-title":"Comparison of the hydrolysis of the three types of natriuretic peptides by human kidney neutral endopeptidase 24.11","volume":"61","author":"Watanabe","year":"1997","journal-title":"Biochem Mol Med"},{"key":"2026040114443761600_xvag075-B15","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1677\/joe.0.1670239","article-title":"Delayed metabolism of human brain natriuretic peptide reflects resistance to neutral endopeptidase","volume":"167","author":"Smith","year":"2000","journal-title":"J Endocrinol"},{"key":"2026040114443761600_xvag075-B16","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1373\/clinchem.2019.306621","article-title":"Educational recommendations on selected analytical and clinical aspects of natriuretic peptides with a focus on heart failure: a report from the IFCC committee on clinical applications of cardiac bio-markers","volume":"65","author":"Kavsak","year":"2019","journal-title":"Clin Chem"},{"key":"2026040114443761600_xvag075-B17","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/ejhf.1342","article-title":"Effects of sacubitril\/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study","volume":"21","author":"Nougu\u00e9","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026040114443761600_xvag075-B18","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.jacc.2018.12.063","article-title":"Effect of neprilysin inhibition on Various natriuretic peptide assays","volume":"73","author":"Ibrahim","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026040114443761600_xvag075-B19","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.jchf.2020.05.012","article-title":"NT-proBNP Response to sacubitril\/valsartan in hospitalized heart failure patients with reduced ejection fraction","volume":"8","author":"Pascual-Figal","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2026040114443761600_xvag075-B20","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jchf.2020.03.002","article-title":"Effects of sacubitril\/valsartan on N-terminal pro-B-type natriuretic peptide in heart failure with preserved ejection fraction","volume":"8","author":"Cunningham","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2026040114443761600_xvag075-B21","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1016\/j.jacc.2019.01.018","article-title":"B-Type Natriuretic peptide during treatment with sacubitril\/valsartan","volume":"73","author":"Myhre","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026040114443761600_xvag075-B22","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1002\/ejhf.1589","article-title":"Sacubitril\/valsartan and B-type natriuretic peptide value: recalculating route","volume":"22","author":"Abellas-Sequeiros","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026040114443761600_xvag075-B23","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1054\/jcaf.2001.23355","article-title":"A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study","volume":"7","author":"Kazanegra","year":"2001","journal-title":"J Card Fail"},{"key":"2026040114443761600_xvag075-B24","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1002\/ejhf.3265","article-title":"Reduced congestion and improved response to a fluid\/sodium challenge in chronic heart failure patients after initiation of sacubitril\/valsartan: the NATRIUM-HF study","volume":"26","author":"Mebazaa","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026040114443761600_xvag075-B25","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1093\/clinchem\/38.9.1785","article-title":"Assay of endopeptidase-24.11 activity in plasma applied to in vivo studies of endopeptidase inhibitors","volume":"38","author":"Yandle","year":"1992","journal-title":"Clin Chem"},{"key":"2026040114443761600_xvag075-B26","doi-asserted-by":"publisher","first-page":"e006946","DOI":"10.1161\/CIRCHEARTFAILURE.119.006946","article-title":"Reverse cardiac remodeling and outcome after initiation of sacubitril\/valsartan","volume":"13","author":"Januzzi","year":"2020","journal-title":"Circ Heart Fail"},{"key":"2026040114443761600_xvag075-B27","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1001\/jama.2019.12821","article-title":"Association of change in N-terminal pro\u2013B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction","volume":"322","author":"Januzzi","year":"2019","journal-title":"JAMA"},{"key":"2026040114443761600_xvag075-B28","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1161\/CIRCULATIONAHA.122.061693","article-title":"Association between sacubitril\/valsartan initiation and mitral regurgitation severity in heart failure with reduced ejection fraction: the PROVE-HF study","volume":"146","author":"Januzzi","year":"2022","journal-title":"Circulation"},{"key":"2026040114443761600_xvag075-B29","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","article-title":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial","volume":"400","author":"Mebazaa","year":"2022","journal-title":"The Lancet"},{"key":"2026040114443761600_xvag075-B30","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jchf.2020.09.013","article-title":"Atrial natriuretic peptide and treatment with sacubitril\/valsartan in heart failure with reduced ejection fraction","volume":"9","author":"Murphy","year":"2021","journal-title":"JACC Heart Fail"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/advance-article-pdf\/doi\/10.1093\/eschf\/xvag075\/67366177\/xvag075.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/13\/2\/xvag075\/67366177\/xvag075.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/13\/2\/xvag075\/67366177\/xvag075.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T18:44:42Z","timestamp":1775069082000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/doi\/10.1093\/eschf\/xvag075\/8524598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,3,16]]},"published-print":{"date-parts":[[2026,3,3]]}},"URL":"https:\/\/doi.org\/10.1093\/eschf\/xvag075","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,3,3]]},"article-number":"xvag075"}}